10:20 AM EST, 11/24/2025 (MT Newswires) -- LivaNova ( LIVN ) said Monday that the provider reimbursement for its neuromodulation treatment, VNS Therapy, under Medicare will increase "significantly," effective Jan. 1, 2026.

The US Centers for Medicare & Medicaid Services assigned VNS Therapy to New Technology Ambulatory Payment Classification 1580 for new patient implants under the 2026 Medicare Hospital Outpatient Prospective Payment System, and moved VNS Therapy end-of-service procedures to Level 5 APC from Level 4, LivaNova ( LIVN ) said.

The company said it expects these changes to improve hospital economics for VNS Therapy, expanding patient access.

Shares of the company were up more than 9% in recent Monday trading.

Price: 60.42, Change: +5.13, Percent Change: +9.27